Expertise in
20
conditions

Dr. Edward L. Pan

Neurology
University Of Texas Southwestern Medical Center
5323 Harry Hines Blvd, 
Dallas, TX 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
20
conditions
University Of Texas Southwestern Medical Center
5323 Harry Hines Blvd, 
Dallas, TX 

Overview

Edward Pan is a Neurologist practicing medicine in Dallas, Texas.

Dr. Pan is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Astrocytoma, Glioma, Glioblastoma, and Brain Tumor.

He is actively involved in clinical research, co-authoring 58 peer reviewed articles and participating in 11 clinical trials.

Specialties

Neurology

Licenses

Psychiatry & Neurology in FL

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

University of Texas Southwestern Medical Center
5323 Harry Hines Blvd, Dallas, TX 75390
Other Locations
Office
2201 Inwood Rd, Dallas, TX 75235

Additional Areas of Focus

Dr. Pan has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Enrollment Status: Recruiting
Publish Date: September 02, 2026
Intervention Type: Drug
Study Drugs: Vismodegib, GSK2256098, Capivasertib, Abemaciclib
Study Phase: Phase 2
GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
Enrollment Status: Recruiting
Publish Date: July 30, 2026
Intervention Type: Drug, Radiation, Biological
Study Drugs: Temozolomide, Lomustine, Regorafenib, Paxalisib, VAL-083
Study Phase: Phase 2/Phase 3
A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination With Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma
A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination With Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Procedure, Biological, Radiation
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 1/Phase 2
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Other, Drug
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2/Phase 3
Genomically-Guided Treatment Trial in Brain Metastases
Genomically-Guided Treatment Trial in Brain Metastases
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Paxalisib, Entrectinib
Study Phase: Phase 2
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2026
Intervention Type: Drug, Radiation
Study Drugs: Concomitant Temozolomide (TMZ), Procarbazine, Adjuvant Temozolomide (TMZ), CCNU, Vincristine
Study Phase: Phase 3
Pilot Study of Abemaciclib With Bevacizumab in Recurrent Glioblastoma Patients With Loss of CDKN2A/B or Gain or Amplification of CDK4/6
Pilot Study of Abemaciclib With Bevacizumab in Recurrent Glioblastoma Patients With Loss of CDKN2A/B or Gain or Amplification of CDK4/6
Enrollment Status: Terminated
Publish Date: August 17, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Bevacizumab
Study Phase: Early Phase 1
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma
Enrollment Status: Completed
Publish Date: January 27, 2025
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Enrollment Status: Suspended
Publish Date: April 03, 2024
Intervention Type: Biological
Study Phase: Phase 3
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: October 23, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 8 Less Clinical Trials

58 Total Publications

Pembrolizumab, Temozolomide and HSPPC-96 Vaccine in Newly Diagnosed Glioblastoma Post-Chemoradiation: Results from a Multi-institutional, Phase 2, Randomized, Placebo-Controlled Trial.
Pembrolizumab, Temozolomide and HSPPC-96 Vaccine in Newly Diagnosed Glioblastoma Post-Chemoradiation: Results from a Multi-institutional, Phase 2, Randomized, Placebo-Controlled Trial.
Journal: medRxiv : the preprint server for health sciences
Published: July 03, 2026
Similar Doctors
Expertise in
18
conditions
Expertise in
18
conditions
Referral may be required

University Of Texas Southwestern Medical Center

5323 Harry Hines Blvd, 
Dallas, TX 
 (0.1 miles away)
214-645-8800
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Benjamin Greenberg is a Neurologist practicing medicine in Dallas, Texas. Dr. Greenberg is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Transverse Myelitis, Optic Neuritis, Neuromyelitis Optica, and Multiple Sclerosis (MS).

Expertise in
27
conditions
Expertise in
27
conditions
Referral may be required

University Of Texas Southwestern Medical Center

5323 Harry Hines Blvd, 
Dallas, TX 
 (0.1 miles away)
214-645-4673
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Justin Jordan is a Neurologist practicing medicine in Dallas, Texas. He has been practicing medicine for over 17 years. Dr. Jordan is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Neurofibromatosis, Schwannomatosis, Neurofibromatosis Type 1 (NF1), Neurofibromatosis Type 2 (NF2), and Tissue Biopsy. Dr. Jordan is currently accepting new patients.

Expertise in
31
conditions
Expertise in
31
conditions
Referral required

James W. Aston Ambulatory Care Center

5303 Harry Hines Blvd., 8th Floor, 
Dallas, TX 
 (0.1 miles away)
214-645-8800
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Steven Vernino is a Neurologist practicing medicine in Dallas, Texas. Dr. Vernino is highly rated in 31 conditions, according to our data. His clinical expertise encompasses Familial Dysautonomia, Orthostatic Hypotension, Low Blood Pressure, Multiple System Atrophy, and Nerve Decompression. Dr. Vernino is currently accepting new patients.

Frequently Asked Questions about Dr. Edward L. Pan

How do I make an appointment with Dr. Edward L. Pan?

You can book an appointment with Dr. Edward L. Pan by calling their office at 214-645-0624. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Edward L. Pan a top-rated expert for Astrocytoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Edward L. Pan is classified as an Elite expert for Astrocytoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Edward L. Pan specialize in?

While Dr. Edward L. Pan is a Neurology, they have specific expertise in Astrocytoma, Glioma, and Glioblastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neurology.

Does Dr. Edward L. Pan participate in research or clinical trials?

Yes. Dr. Edward L. Pan has published 58 articles and abstracts on conditions like Astrocytoma. You can view a list of Dr. Edward L. Pan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Edward L. Pan accept my insurance?

Dr. Edward L. Pan accepts most major insurance plans, including Blue Cross Blue Shield and Health Care Services Corporation. We recommend calling the office directly at 214-645-0624 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Pan's expertise for a condition
ConditionClose
View All 13 Distinguished Conditions
View All 19 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile